Retinoid receptor alpha and Beta expression in serous ovarian tumors.
The expression of retinoid acid receptors alpha (RARalpha) and beta (RARbeta) and estrogen receptor alpha (ERalpha) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival. RARalpha was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001). In stage III, G3 serous carcinoma, increased RARalpha expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival.
Daponte
A
A
Department of Obstetrics and Gynecology, University Hospital of Larissa, Larissa, Greece. dapontea@otenet.gr
Kostopoulou
E
E
Papandreou
C N
CN
Chiotoglou
I
I
Voutsadakis
I
I
Vanakara
P
P
Minas
M
M
Nakou
M
M
Kallitsaris
A
A
Kollia
P
P
Koukoulis
G
G
Messinis
I E
IE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D018394:CA-125 Antigen / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D018293:Cystadenoma, Serous / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D018572:Disease-Free Survival; D047628:Estrogen Receptor alpha / Q000032:analysis*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D011860:Radiography, Abdominal; D018168:Receptors, Retinoic Acid / Q000032:analysis*; D000072482:Retinoic Acid Receptor alpha; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D047628:Estrogen Receptor alpha; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; C082925:retinoic acid receptor beta